In this study, we first used the data of the Oncomine database to analyze the difference in MYL5 gene expression, and the results showed that compared with corresponding normal tissues, the expression of MYL5 was decreased in breast cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, and leukemia, but was elevated in kidney cancer (Figure 1(a)). This evidence concerns the gene MYL5 and head and neck cancer.